Response Phenotype As a Predictive Biomarker to Guide Treatment With Targeted Therapies
Menée sur des patients atteints d'un cancer colorectal métastatique traité par cetuximab, cette étude évalue, en fonction de la présence ou non d'une mutation du gène KRAS, l'association entre une réduction précoce de la taille tumorale et la survie à long terme
Tumor response is one of the oldest biomarkers in solid tumor oncology, first assessed by manual palpation and simple radiographs, and then in recent decades by computed tomography, magnetic resonance imaging, or more advanced imaging. Clinicians have recognized intuitively that patients with responding tumors do better than those with no response,and those with tumor growth do worse. In this way, clinicians use tumor response to help guide the decision about which patients might benefit from additional treatment despite toxicity, which patients might do better with dose adjustment or delay, and which patients instead require a change in therapy...
Journal of Clinical Oncology , éditorial, 2013